Named author:

Santos-Lima E, B’Chir S, Lane A. Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™) following primary series administration at 2, 4, 6 months of age in Latin America.  Vaccine 2013;31:1255-1258

Thisyakorn U, Lane A. Routine newborn hepatitis B immunization. Infect Dis Clin Prac 2011;19(5):326-331

Lefèvre G, Carpenter P, Souppart C, Schmidli H, Martin JM, Lane A, Ward C, Amakye D. Interaction trial between artemether-lumefantrine (Riamet^®) and quinine in healthy subjects. J Clin Pharmacol 2002:42;1147-1158

Lane AJP, Wathes DC. An electronic nose to detect changes in perineal odors associated with estrus in the cow. J Dairy Sci 1998:81;2145-2150

Lane AJP, Coombs RC, Evans DH, Levin RJ. Effect of feed interval and feed type on splanchnic haemodynamics. Arch Dis Child Fetal Neonatal Ed 1998:79;F49-F53

Lane AJP, Coombs RC, Evans DH, Levin RJ. Effect of caffeine on neonatal splanchnic blood flow. Arch Dis Child Fetal Neonatal Ed 1999:80;F128-F129

Lane A, Levin RJ. Enhanced electrogenic secretion in vitro by small intestine from glucagon-treated rats: implications for the diarrhoea of starvation. Exp Physiol 1992:77;645-648

Cited for medical writing support:

McMahon R, Toepfer S, Sattler N, Schneider M, Narciso-Abraham M, Hadl S, et al. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infect Dis 2024 (in press)

Buerger V, Maurer G, Kosulin K, Hochreiter R, Larcher-Senn J, Dubischar K, et al. Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine. J Trav Med 2024 (in press)

Curie A, Lion-Francois L, Valayannopoulos V, Perreton N, Gavanon M, Touil N, et al. Clinical characteristics, developmental trajectory, and caregiver burden of patients with creatine transporter deficiency (SLC6A8). Neurology 2024; 102(8): e209243.

Boisnard F, Manson C, Serradell L, Macina D. DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure. Exp Rev Vacc 2023; 22(1): 1196-213

Avila Aguero ML, Castillo JBD, Falleiros-Arlant LH, et al. Risks of low vaccination coverage and strategies to prevent the resurgence of vaccine-preventable diseases in infants in the COVID-19 pandemic scenario: recommendations for Latin America and the Caribbean by the group of experts on infant immunization for Latin America. Exp Rev Vacc 2023;22(1):1091-101

Mangarule S, Siddaiah P, Kawade A, Dhati RM, Padmavathi IV, Palkar S, et al. Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP~T vaccine versus separate DTwP-HB-PRP~T and IPV vaccines and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP~T administered with an MMR vaccine in healthy infants in India. Pediatr Inf Dis J. 2023;42(12):1128-1135

Sanchez L, Rungmaitree S, Kosalaraska P, Jantarabenjakul W, Leclercq J, Yaiprayoon Y, et al. Immunogenicity and safety of a hexavalent DTwP-IPV-HB-PRP~T vaccine versus separate DTwP-HB-PRP~T, bOPV, and IPV vaccines administered at 2, 4, 6 months of age concomitantly with rotavirus and pneumococcal conjugate vaccines in healthy infants in Thailand. Pediatr Inf Dis J. 2023;42(8):711-718

Clark LR, Johnson DR. Safety and clinical benefits of Adacel® and Adacel®-Polio vaccination in pregnancy: a structured literature review. Infect Dis Ther. 2023 Aug;12(8):1955-2003

Torres-Martinez C, Chaparro E, Marino AC, Falleiros-Arlant LH, Camacho-Moreno G, Castillo ME, et al. Recommendations for modernizing infant vaccination schedules with combination vaccines in Colombia and Peru. Rev Panam Salud Publica. 2023;47:e24

Maertens K, Orije MRP, Huoi C, Boisnard R, Lyabis O. Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP~T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy. Vaccine. 2023 Jan 16;41(3):795-804

Mangarule S, Prashanth S, Kawade A, Ravi MD, Padmavathi IV, Palkar S, et al. Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP~T vaccine and non-inferiority to separate DTwP-HB-PRP~T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study. Vaccine X. 2022;12:100216

Trouiller JB, Macabeo B, Poll A, Howard D, Buckland A, Sivignon M, et al. Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial. BMJ Open. 2022;12(11):e063700

Serresse L, Guerder A, Dedonder J, Nion N, Lavault S, Morelot-Panzini C, et al. ‘You can’t feel what we feel’: Multifaceted dyspnoea invisibility in advanced chronic obstructive pulmonary disease examined through interpretative phenomenological analysis. Palliat Med. 2022;36(9):1364-73

Huoi C, Vargas-Zambrano J, Macina D, Vidor E. A combined DTaP-IPV vaccine (Tetraxim®/Tetravac®) used as school-entry booster: a review of more than 20 years of clinical and post-marketing experience. Exp Rev Vacc 2022:1-17

Mangarule S, Palkar S, Mitra M, Ravi MD, Singh R, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Patnaik BN, Jordanov E, Noriega F. Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP~T vaccine versus separate DTwP-HB-PRP~T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP~T in healthy infants in India. Vaccine X 2022;11:100190

Rigoine de Fougerolles T, Damm O, Ansaldi F, Chironna M, Crépey P, de Lusignan S, Gray I, Guillen JM, Kassianos G, Mosnier A, Ortiz de Lejarazu R, Pariani E, Puig-Barbera J, Schelling J, Trippi F, Vanhems P, Wahle K, Watkins J, Rasuli A, Vitoux O, Bricout H. National influenza surveillance systems in five European countries: a qualitative comparative framework based on WHO guidance. BMC Public Health 2022;22(1): 1151

Fernández-Jimenez E, Diz-Arias E, Peral A. Improving ocular surface comfort in contact lens wearers. Contact Lens and Anterior Eye 2022;45(3):101544

Mangarule S, Palkar S, Mitra M, Ravi MD, Dubey AP, Moureau A, et al. Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP approximately T vaccine versus separate DTwP-HB-PRP approximately T and IPV vaccines in healthy infants in India. Vaccine X. 2022;10:100137

Vergari C, Skalli W, Clavel L, Demuynck M, Valentin R, Sandoz B, Similowski T, Attali V. Functional analysis of the human rib cage over the vital capacity range in standing position using biplanar X-ray imaging. Comput Biol Med. 2022;144:105343

Dres M, Gama de Abreu M, Merdji H, Muller-Redetzky H, Dellweg D, Randerath WJ, Mortaza S, Jung B, Bruells C, Morer O, Scharffenberg M, Jaber S, Besset S, Bitter T, Geise A, Heine A, Malfertheiner MV, Kortgen A, Benzaquen J, Nelson T, Uhrig A, Monig O, Meziani F, Demoule A, Similowski T, Rescue- Study Group Investigators. Randomised clinical study of temporary transvenous phrenic nerve stimulation in difficult-to-wean patients. Am J Respir Crit Care Med. 2022;205(10):1169-1178

Rigoine de Fougerolles T, Puig-Barbera J, Kassianos G, Vanhems P, Schelling J, Crepey P, Ortiz de Lejarazu R, Ansaldi F, Fruhwein M, Galli C, Mosnier A, Pariani E, Rasuli A, Vitoux O, Watkins J, Weinke T, Bricout H. A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom. Influenza Other Respir Viruses. 2022;16(3):417-428

Romero M, Rodriguez D, Caicedo M, Benchabene D, Lopez J-G. Cost-minimization and budget impact analysis of a hexavalent vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization. Value in Health Regional Issues. 2021;26:150-159

Varghese K, Bartlett W, Zheng L, Bookhout S, Vincent D, Huleatt J, Brown M, Mangarule S, Noriega F, Hodge S. A new electrochemiluminescence-based multiplex assay for the assessment of human antibody responses to Bordetella pertussis vaccines. Infectious Diseases and Therapy. 2021;10(4):2539-61

Kassianos G, Banerjee A, Baron-Papillon F, Hampson AW, McElhaney JE, McGeer A, Rigoine de Fougerolles T, Rothholz M, Seale H, Tan LJ, Thomson A, Vitoux O. Key policy and programmatic factors to improve influenza vaccination rates based on the experience from four high-performing countries. Drugs in Context 2021;10:2020-9-5 doi 10.7573/dic.2020-9-5

de Bruyn G, Gordon DL, Steiner T, Tambyah P, Cosgrove C, Martens M, Bassily E, Chan ES, Patel D, Chen J, Torre-Cisneros J, Fernando De Magalhaes Francesconi C, Gesser R, Jeanfreau R, Launay O, Laot T, Morfin-Otero R, Oviedo-Orta E, Park YS, Piazza FM, Rehm C, Rivas E, Self S, Gurunathan S. Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Inf Dis 2021;21(2):252-262

Virta M, Soininen A, Patel DM, Petit C, Tabar C, Lyabis O. Persistence of hepatitis B immune memory until 6 Years of age following hexavalent DTaP-IPV-HB-PRP~T vaccination in a 3-, 5- and 11- to 12-month schedule and response to a subsequent hepatitis B challenge vaccination. Pediatr Infect Dis J 2021;40(1):e28-e30

Souki S, Cochener B, Labetoulle M, Güell JL. A Phase IV clinical study to evaluate the effects of an intracameral combined mydriatic and anesthetic agent and standard topical mydriatics and anesthetics on the ocular surface after cataract surgery. Journal of Cataract and Refractive Surgery 2021;47(5):570-578 doi 10.1097/j.jcrs.0000000000000491

Koen A, Madhi S, Lyabis O, Vidor E, Cowper B, Marais T, Patel D, Vigne C. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother 2020 doi 10.1080/21645515.2020.1839289

Fajnkuchen F, Delyfer M-N, Conrath J, Baillif S, Mrejen S, Srour M, Bellamy J-P, Dupas B, Lecleire-Collet A, Meillon C, Bonicel P, Hobeika M, Giocanti-Aurégan A. Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections. Acta Diabetologica 2020;57:1081-1091

Espul C, Cuello H, Lo Castro I, Bravo C, Thollot Y, Voznica J, Vigne C, Coudeville L. Statistical modeling alongside observational data predicts long-term immunogenicity of one dose and two doses of pediatric hepatitis A vaccine in the Mendoza province of Argentina. Vaccine 2020;38(7):1715-1722

Nakayama T, Vidor E, Tsuzuki D, Nishina S, Sasaki T, Ishii Y, Mizukami H, Tsuge H. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. Journal of Infection and Chemotherapy 2020;26:651-659

Trosini-Désert V, Lafoeste H, Regard L, Malrin R, Galarza-Jimenez M-A, Esteban Amarilla CE, Delrieu J, Fôret D, Melloni B, El-Khouari F, Similowski T. A telemedicine intervention to ensure the correct usage of inhaler devices. Telemedicine and eHealth 2020;26(11):1336-1344

Julienne R, Garcin T, Crouzet E, He Z, Renault D, Thuret G, Gain P. Evaluation of corneal epithelial wound healing after penetrating keratoplasty in patients receiving a new matrix therapy agent (regenerating agent). Eur J Ophthalmol 2020 Jan;30(1):119-124 doi: 10.1177/1120672118808971Shi N, Rasuli A, Thollot Y. Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study. Hum Vaccin Immunother 2019;15(3):748-754

Raux M, Navarro-Sune X, Wattiez N, Kindler F, Le Corre M, Decavele M, Demiri S, Demoule A, Chavez M, Similowski T Adjusting ventilator settings to relieve dyspnoea modifies brain activity in critically ill patients: an electroencephalogram pilot study. Scientific Reports 2019;9(1):16572

Vu DT, Thuy TP, Radigue C, Nguyen DQ, Da Costa X, B’Chir S, Vidor E. Immunogenicity and safety of fully liquid hexavalent booster vaccine given to Vietnamese infants previously vaccinated at birth with hepatitis B vaccine. Southeast Asian Journal of Tropical Medicine and Public Health 2019;50(6):1078-1089

Namazova-Baranova LS, Kharit SM, Perminova OA, Romanenko W, Osipova IV, Asatryan AG, Goldstein AV, B’Chir S, Lyabis O. Safety and immunogenicity of fully liquid hexavalent DTaP-IPV-HepB-Hib vaccine in healthy infants in Russian Federation. Epidemiology and Vaccinal Prevention 2019;18(3)28-39 [Russian] doi: 10.31631/2073-3046-2019-18-3-28-39

Aptel F, Pfeiffer N, Schmickler S, Clarke J, Lavin-Dapena C, Moreno-Monatañes J, Zarnowski T, Csutak A, Jugaste T, Volksone L, Astakhov YS, Coupier L, Nordmann J-P, Stalmans I, T2347 Study Group. Noninferiority of preservative-free vesrus BAK-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2019;28-498-506

Madhi S, López P, Zambrano B, Jordanov E, B’Chir S, Noriega F, Feroldi E. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vacc Immunother 2019;15(3):658-668 doi: 10.1080/21645515.2018.1546524

Martinón-Torres F, Diez-Domingo J, Feroldi E, Jordanov E, B’Chir S, Da Costa X. Evaluation of a hexavalent-pentavalent-hexavalent infant primary vaccination series followed by a pentavalent booster vaccine in healthy infants and toddlers. Pediatr Inf Dis J 2019;38(3):317-322 doi: 10.1097/INF.0000000000002231

Bakhache P, Virey B, Bienenfeld C. Knowledge and practices regarding infant vaccination: results of a survey of French physicians. Eur J Ped 2018: doi 10.1007/s00431-018-03314-3

dos Reis D, Fraticelli L,Bassand A,Manzo-Silberman S, Peschanski N, Charpentier S, Elbaz M, Savary D, Bonnefoy-Cudraz E, Laribi S, Henry P, Guerraoui A, Tazarourte K, Chouihed T, El Khoury C. Impact of renal dysfunction on the management and outcome of acute heart failure: results from the French prospective, multicentre, DeFSSICA survey. BMJ Open 2019;9(1):e022776 doi: 10.1136/bmjopen-2018-022776

Heitzmann M, Thumm D, Baudouin C. A review of the efficacy, safety and tolerability of Lacrycon® eye drops for the treatment of dry eye syndrome. J Français d’Opthalmol 2019;42(6):642-654

Payot F, Lachaux A, Lalanne F, Kalach N. Randomized trial of a yogurt-type amino acid-based formula in infants and children with severe cow’s milk allergy. J Ped Gastroenterol & Nutr 2018;66(1):135-140

Prymula R, Kieninger D, Feroldi E, Jordanov E, B’Chir S, DaCosta X. Immunogenicity and safety of primary and booster vaccinations of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine in healthy infants and toddlers in Germany and the Czech Republic. Pediatr Inf Dis J 2018;37(8):823-830

Kosalaraksa P, Chokephaibulkit K, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S, B’Chir S, Da Costa X, Vidor E. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months. Hum Vacc Immunother 2018;14(5):1257-1265

Doan S, Bremond-Gignac D, Chiambaretta F.Comparison of the effect of a hyaluronate-trehalose solution to hyaluronate alone on ocular surface disease index in patients with moderate to severe dry eye. Curr Med Res Opin 2018;34(8):1373-1376

Le Pen C, Palazzo L, Napoléon B. A health economic evaluation of needle-based Confocal Laser Endomicroscopy for the diagnosis of pancreatic cysts. Endosc Int Open 2017;05:E987-E995

Espul C, Benedetti L, Linares M, Cuello H, Lo Castro I, Thollot Y, Rasuli A. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. Hum Vacc Immunother 2017:13(11);2707-2712

Nuijts R, Mencucci R, Viaud-Quentric K, Elena P-P, Olmière C, Behndig A. Good ocular tolerance in rabbits after intracameral administration of Mydrane®, a fixed combination of tropicamide, phenylephrine, and lidocaine, with and without rinsing. J Cat Refract Surg 2017;43(5):673-679

López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B’Chir S, Zambrano B. A randomized, controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America. Pediatr Inf Dis J 2017;36(11):e272-e282

Ceyhan M, Yildirim I, Tezer H, Devrim I, Feroldi E. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers. Turk J Med Sci 2017;47:1247-1256

Matsuoka O, Patel DM, Sasaki S, Oka H, Sasaki T, Pietrobon PJ, Laot T, Bouckenooghe A, Menezes J, de Bruyn G. Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults. Jpn J Chemother 2017;65(2):183-191

Kim Y-K, Vidor E, Kim HM, Shin SM, Li K-Y, Cha S-H, Ma SH, Kim DH, Lee J, Park SE, Lee H, Kim J-D, Kim KH, Kim K-H, Kim J-H, A3L31 Study Group. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea. Vaccine 2017;32:4022-4028

Vesikari T, Silfverdal SA, Jordanov E, Feroldi E. A radnomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5-, and 11- to 12-month schedule. Pediatr Inf Dis J 2017;36(1):87-93

Chiambaretta F, Doan S, Labetoulle M, Rocher N, Fekih LE, Messaoud R, Khairallah M, Baudouin C. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol 2017;27(1):1-9

Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid hexavalent vaccine in Indian infants. Ind Pediatr 2017;54:15-20

Vidor E, Soubeyrand B. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Exp Rev Vaccines 2016 15(12):1575-1582

Kassianos G, Blank P, Falu-Pecurariu O, Kuchar E, Kyncl J, Ortiz de Lejarazu R, Nitsch-Osuch A, van Essen GA. Influenza vaccination: key facts for general practitioners based in Europe-a synthesis by European Experts based on national guidelines and best practices in the United Kingdom and the Netherlands. Drugs in Context 2016;5:212293

Aptel F, Choudry R, Stalmans I. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2016 Aug;32(8):1457-63

Chiambaretta F, Doan S, Labetoulle M, Rocher N, Fekih LE, Messaoud R, Khairallah M, Baudouin C. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol 2016 Jul 20:0

de Bruyn G, Saleh J, Workman D3, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, Trevino M, van Cleeff M, Foglia G, Ozol-Godfrey A, Patel DM, Pietrobon PJ, Gesser R; H-030-012 Clinical Investigator Study Team. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016 Apr 27;34(19):2170-8

Viaud-Quentric K, Lefranc-Julien S, Feraille L, Elena PP. Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient. J Fr Ophthalmol 2016 Feb;39(2):156-63

Kim DS, Jang GC, Cha SH, Choi SH, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Bang J, Naimi Z, Bouckenooghe A, Bosch-Castells V, Houillon G. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea. Pediatr Infect Dis J. 2016 Feb;35(2):e60-4

Kassianos G. The importance of seasonal influenza vaccination as a travel vaccine. Journal of BGTHA 2015;XXV: 13-14

Guillemin I, Marrel A, Beriot-Mathiot A, Doucet C, Kazoglou O, Luxemburger C, Reygrobellet C, Arnould B. How do Clostridium difficile infections affect nurses’ everyday hospital work: a qualitative study. Int J Nurs Prac 2015;21 (Suppl. 2):38-45

Lobzin YV, Babachenko IV, Shamsheva OV, Tetenkova AA, Bakhareva NV, Boitsov VP, Zvereva NN. Retrospective study of the clinical epidemiological characteristics of pertussis in infants prior to their first vaccination in the Russian Federation. Inf Dis Ther 2015 doi: 10.1007/s40121-015-0059-9

Kassianos G. European healthcare workers’ willingness to be vaccinated against seasonal influenza: current situation and suggestions for improvement. Drugs in Context 2015:4;212268 doi: 10.7573/dic.212268

Guillemin I, Marrel A, Lambert J, Beriot-Mathiot A, Doucet C, Kazoglou O, Luxemburger C, Reygrobellet C, Arnold B. Patients’ experience and perception of hospital-treated Clostridium difficile infections: a qualitative study. Patient 2014: doi 10.1007/s40271-013-0043-y

Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine co-administered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Inf Dis J 2013:32(8):889-897

Eckmann C, Wasserman M, Latif F, Roberts G, Beriot-Mathiot A. Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries. Eur J Health Econ 2013 (Epub ahead of print: doi 10.1007/s10198-013-0498-8)

Paterson L. The European Medicines Agency’s Article 58 procedure: reflections on the first approval for a vaccine. Regulatory Rapporteur 2013;10(4):19-23

Dutta AK, Verghese VP, Pemde H, Mathew LG, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP~T vaccine (Pentaxim) booster dose during the second year of life in Indian children primed with the same vaccine. Ind Pediatr 2012;49:793-798

Becerra A, Gutiérrez M, Aranza C, Galán JF, Macias M, Zambrano B, Santos-Lima E. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine 2012;30:6492-6500

Macías M, Lanata CF, Zambrano B, Gil AI, Amemiya I, Mispireta M, Ecker L, Santos-Lima E. Safety and Immunogenicity of an Investigational Fully Liquid Hexavalent: DTaP IPV Hep B PRP T Vaccine at 2, 4, 6 Months of Age Compared to Licensed Vaccines in Latin America. Pediatr Infect Dis J. 2012;31(8):e126-e132

Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children. Southeast Asian J Trop Med Pub Health 2012;43(3):687-697

Foglia G, Shah S, Luxemburger C, Pietrobon PJF. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012;30:4307-4309

Lanata C, Zambrano B, Ecker L, Amemiya I, Gil A, Santos-Lima E. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in Peru. Vaccine and Vaccination 2012;3(1): dx.doi.org/10.4172/2157-7560.1000128

Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b vaccine among Thai children at 18-19 months of age. Southeast Asian J Trop Med Pub Health 2012;43(2):442-454

Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012;20:2245-2249

Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012;31(1):e24-e30

Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18-19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. South Afr Med J 2011;101(12):879-833

Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML Zhang YP, Ortiz E. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP~T vaccine compared to separate vaccines (DTaP, PRP~T and IPV) following primary vaccination of healthy infants in the People’s Republic of China. Vaccine 2011;29:9337-9344

Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP IPV//PRP~T vaccine (Pentaxim™): a review of 16 years’ clinical experience. Expert Rev Vaccines. 2011;10(7):981-1005

Nates SV, Frias M, Belfiore S, Isa MB, Martinez LC, Chuit R, Armoni J, Luxemburger C. Effect on seroprevalence of anti-poliovirus antibodies and on vaccination coverage of the implementation of a DTwP-IPV-Hib vaccination programme in a South American city. Epidemiol Infect 2011;139:826-835

Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diptheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J 2011;30(6):e88-e96

Madhi SA, Mitha I, Cutland C, Groome M, Santos-Lima E. Immunogenicity and Safety of an Investigational Fully Liquid Hexavalent Combination Vaccine Versus Licensed Combination Vaccines at 6, 10, and 14 Weeks of Age in Healthy South African Infants. Pediatr Infect Dis J 2011;30(4):e68-e74

Kosalaraska P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4 and 6 months of age in Thai infants. Int J Infect Dis 2011;15(4):e249-56

Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. South Afr Med J 2011;101(2):126-131

Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, Park SE, Ma SH, Chang JK, Guitton F, Ortiz E, Kang JH. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea. Vaccine 2011;29:1551-1557

Li RC, Li FX, Li YP, Hou QM, Li CG, Li, YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Lu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.  Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus influenza type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Vaccine 2011;29:1913-1920

Tregnaghi MW, Voelker R, Santos-Lima E, Zambrano B. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine 2010;28(20):3595-601

Dutta A, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Immunogenicity and safety of a pentavalent diphtheria, tetanus, aceullular pertussis, inactivated poliovirus, Haemophilus influenza type b conjugate combination vaccine (Pentaxim™) with hepatitis B vaccine. Ind Pediatr 2009;46:975-982